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Abstract. The mammalian target of rapamycin (mTOR) plays 
a key role in the regulation of cellular metabolism, growth and 
proliferation. It forms two multi-protein complexes known as 
complex 1 (mTORC1) and 2 (mTORC2). Raptor and Rictor 
are the core proteins for mTORC1 and mTORC2, respectively. 
This study examines the relationship between mTORC1, 
Rictor and Raptor mRNA expression and human breast 
cancer. Furthermore, the correlation between mTORC1 and 
hTERT was investigated. Breast cancer tissues (n=150) and 
normal tissues (n=31) were analysed using reverse transcrip-
tion and quantitative PCR. Transcript levels were correlated 
with clinicopathological data. Higher mTOR expression was 
noted in breast cancer tissue (P=0.0018), higher grade tumours 
(grade 2 vs. 3, P=0.047), in ductal tumours (P=0.0014), and 
was associated with worse overall survival (P=0.01). Rictor 
expression was significantly higher in background breast 
tissues compared with tumours and was inversely related to 
the Nottingham Prognostic Index (NPI1 vs. 2, P=0.03) and 
tumour grade (grade 1 vs. 3, P=0.01) and was associated with 
better overall (P=0.037) and disease-free survival (P=0.048). 
The mRNA expression of Raptor was higher in tumours 
compared with normal tissues. Furthermore, the expression of 
Raptor was associated with a higher tumour grade (grade 1 
vs. 3, P=0.027). A highly significant positive correlation 
between mTOR and hTERT (P<0.00001) was observed. These 
observations are consistent with the role of mTORC1 in the 
anti-apoptosis pathway and suggest that selective inhibitors of 
mTORC1 may be more efficacious in human breast cancer. Our 
findings support the hypothesis that mTORC1 is an important 
upregulator of telomerase in breast cancer.
Introduction
The mammalian target of rapamycin (mTOR) plays a key 
role in the regulation of cellular metabolism, growth and 
prolifer ation. It was found to mediate the anti-proliferative 
activities of rapamycin and its analogues (rapalogues). It 
forms two multi-protein complexes known as complex 1 
(mTORC1) and 2 (mTORC2). Raptor and Rictor are the core 
proteins for mTORC1 and mTORC2, respectively, known to be 
essential for the integrity of their respective complexes (1,2). 
Rheb (Ras homologue enriched in brain) is a key activator of 
mTORC1. There is a growing body of evidence that mTORC1 
is upregulated in many types of cancers and plays a role in 
carcinogenesis (3).
Rapalogues have been clinically proven in the case of renal 
cell carcinoma (4,5). However, this success is yet to be repli-
cated in the case of other cancers. A greater understanding 
of the role of mTOR in various types of cancers is needed 
to determine therapeutic strategies. To this end, studies have 
been carried out to identify potential markers of rapamycin 
sensitivity, as well as additional therapeutic agents (6,7).
The aim of the study was to investigate the mRNA expres-
sion of mTORC1, Rictor, Raptor and Rheb in human breast 
cancer and examine the relationship between their expres-
sion and clinicopathological parameters. Furthermore, the 
correlation between mTORC1 and human telomerase reverse 
transcriptase (hTERT; the catalytic subunit of telomerase) was 
investigated.
Materials and methods
Samples. Tissue samples were collected after informed consent 
with ethical approval as per contemporaneous institutional 
guidelines. Immediately after surgical excision, a tumour 
sample was taken from the tumour area, while another was 
taken from the associated non-cancerous tissue (ANCT) within 
2 cm of the tumour, without affecting the assessment of tumour 
margins. Breast cancer tissues (n=150) and normal background 
tissues (n=31) were collected and stored at -80˚C in liquid 
nitrogen until the commencement of this study.
All the patients were treated according to local guide-
lines, following discussions in multidisciplinary meetings. 
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Patients undergoing breast-conserving surgery also under-
went radiotherapy. Hormone-sensitive patients received 
tamoxifen. Hormone-insensitive cases, high-grade cancer, 
and node-positive cases were treated with adjuvant therapy. 
Clinicopathological data (Table I) were collected from the 
patient charts and collated in an encrypted database.
RNA extraction kits and reverse transcription kits were 
obtained from AbGene, Ltd. (Surrey, UK). PCR primers 
were designed using Beacon Designer (Premier Biosoft 
International, Ltd., Palo Alto, CA, USA) and synthesized by 
Invitrogen, Ltd. (Paisley, UK). Custom made Hot Start Master 
Mix for quantitative PCR was from AbGene (8).
Tissue processing, RNA extraction and cDNA synthesis. 
Approximately 10 mg of cancerous tissue was homogenised. A 
larger amount of ANCT (20-50 mg) was used as its high fat 
content made it difficult to obtain sufficient RNA for analysis. 
The concentration of RNA was determined using a UV spectro-
photometer (Wolf Laboratories, York, UK) to ensure adequate 
amounts of RNA for analysis. Reverse transcription was 
carried out using a reverse transcription kit (AbGene) with an 
anchored oligo(dT) primer using 1 mg of total RNA in a 96-well 
plate to produce cDNA. The quality of cDNA was verified 
using β-actin primers (5'-ATGATATCGCCGCGCTCGTC-3' 
and 5'-CGCTCGGTGAGGATCTTCA-3') (8).
Quantitative analysis. Transcripts of the cDNA library 
were determined using real-time quantitative polymerase 
chain reaction (qPCR) based on Amplifluor technology. The 
PCR primers were designed using Beacon Designer soft-
ware, but an additional sequence, known as the Z sequence 
(5'-ACTGAACCTGACCGTACA-3'), which is complementary 
to the universal Z probe (Intergen, Inc., Oxford, UK) was 
added to the primer. The primers used are detailed in Table II.
The reaction was carried out under the following conditions: 
94˚C for 12 min and 50 cycles of 94˚C for 15 sec, 55˚C for 40 sec 
and 72ºC for 20 sec. The levels of each transcript were gener-
ated from a standard plasmid which contained the specific DNA 
sequence that was simultaneously amplified within the samples. 
With every run of the PCR, a negative and positive control was 
employed, using a known cDNA sequence (8).
Statistical analysis. Analysis of the data was performed using 
the Minitab 12 statistical software package (Minitab, Ltd., 
Coventry, UK) using a custom-written macro (Stat06e.mtb). 
Medians were compared using the Mann-Whitney U-test, 
while the means were compared using the two-sample t-test. 
The transcript levels within the breast cancer specimens were 
compared to those of the ANCT and correlated with clinico-
pathological data collected over a 10-year follow-up period.
Table I. Clinical data describing the patient cohort.
Parameter No. of patients
Node status
 Node positive 65
 Node negative 55
Tumour grade
 1 23
 2 41
 3 56
Tumour type
 Ductal 88
 Lobular 14
 Medullary 2
 Tubular 2
 Mucinous 4
 Other 4
TNM staging
 1 69
 2 40
 3 7
 4 4
Clinical outcome
 Disease-free 81
 With local recurrence 5
 Alive with metastasis 7
 Succumbed to breast cancer 20
Table II. Primers used in the RT-PCR analysis.
Gene Primer sequence
mTORF1 CTGCAGAAGAAGGTCACT
mTORZr1 ACTGAACCTGACCGTACAAAGGAGATGGAACGGAAG
RHEBF1 TTGGTTGGGAATAAGAAAGA
RHEBZr1 ACTGAACCTGACCGTACAAAAAGCTGCATTCCAAGAT
RaptorF1 TGAACACCGGACCATGAC
RaptorZr1 ACTGAACCTGACCGTACACAATGAGGTTTCCCTGAAG
RictorF1 AACTTGCAAAACAGTGTGAA
RictorZr1 ACTGAACCTGACCGTACAATATCACAGCCTTGTTTGGT
β-actin forward ATGATATCGCCGCGCTCGTC
β-actin reverse CGCTCGGTGAGGATCTTCA
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P-values <0.05 were considered significant, whereas P-values 
between 0.05 and 0.10 were considered marginally significant. 
Correlations between the expression levels of the molecules 
were studied using the Pearson product moment correlation test.
For purposes of the Kaplan-Meier survival analysis, the 
samples were divided arbitrarily into high and low transcrip-
tion groups, with the value for the moderate prognostic group 
as defined by Nottingham prognostic index (NPI) serving as 
the dividing line. Survival analyses were performed using 
PSAW18 (SPSS, Inc., Chicago, IL, USA).
Results
Significantly higher mTORC1 mRNA transcript levels were 
found in the breast cancer specimens compared to the normal 
glandular tissue (P=0.0018). The expression of mTORC1 
mRNA was demonstrated to increase with increasing NPI 
(from 53 for NPI1 to 219 for NPI3) and tumour grade, and this 
difference reached statistical significance when comparing 
grade 2 with grade 3 (37 vs. 159, P=0.047). mTORC1 expres-
sion was found to be higher in ductal tumours compared with 
non-ductal tumours (P=0.0014). The patients who developed 
recurrent disease or died from breast cancer had higher expres-
sion levels of mTORC1 than those who had been disease-free 
after a median follow-up period of 10 years (P=0.17). Higher 
expression levels were significantly associated with worse 
overall survival (P=0.01; Table III, Figs. 1 and 2).
The mTORC2 core protein Rictor mRNA expression 
showed an opposing trend to mTORC1 with higher levels 
being found in normal breast tissue, lower NPI stage (NPI1 vs. 
2, P=0.03) and lower tumour grade (grade 1 vs. 3, P=0.01 and 
grade 2 vs. 3, P=0.03). Patients with higher Rictor expression 
had a significantly better disease-free (P=0.048) and overall 
(P=0.037) survival (Table IV, Figs. 3 and 4).
Table III. Comparison of mTOR mRNA expression levels in 
subgroups within the cohort.
Patient and tumour
characteristics mTOR, mean (SD) P-value
Tumour grade
 1 vs. 2 59 (123) vs. 36.9 (98.9) 0.50
 1 vs. 3 59 (123) vs. 139 (349) 0.16
 2 vs. 3 36.9 (98.9) vs. 139 (349) 0.047
NPI
 1 vs. 2 53 (127) vs. 102 (306) 0.36
 1 vs. 3 53 (127) vs. 219 (437) 0.17
 2 vs. 3 102 (306) vs. 219 (437) 0.36
TNM
 1 vs. 2 61 (134) vs. 130 (383) 0.31
 1 vs. 3 61 (134) vs. 93 (218) 0.74
 1 vs. 4 61 (134) vs. 36.3 (55.7) 0.48
 2 vs. 3 130 (383) vs. 93 (218) 0.75
 2 vs. 4 130 (383) vs. 36.3 (55.7) 0.19
 3 vs. 4 93 (218) vs. 36.3 (55.7) 0.57
Survival
 DF vs. LR 63 (153) vs. 45.5 (82.7) 0.63
 DF vs. DR 63 (153) vs. 20.5 (31.7) 0.068
 DF vs. D 63 (153) vs. 324 (585) 0.12
 DF vs. LR/DR/D 63 (153) vs. 191 (449) 0.17
Mean mTOR mRNA expression levels (copy number) in a cohort of 
150 breast cancer patients; a comparison between subgroups with 
different tumour grade, Nottingham prognostic index (NPI), TNM 
stage and clinical outcome. SD, standard deviation; DF, disease-free 
survival; LR, local disease recurrence; DR, distant disease recurrence; 
D, death from breast cancer.
Figure 1. Disease-free survival curve for mTORC1. Curve A, lower trans-
cription group as determined by moderate prognostic group as defined by 
NPI serving as the dividing line; Curve B, higher transcription group as 
determined by moderate prognostic group as defined by NPI serving as the 
dividing line; X-axis, follow-up in months; Y-axis, cumulative survival.
Figure 2. Overall survival curve for mTORC1. Curve A, lower transcription 
group as determined by moderate prognostic group as defined by NPI serving 
as the dividing line; Curve B, higher transcription group as determined by 
moderate prognostic group as defined by NPI serving as the dividing line; 
X-axis, follow-up in months; Y-axis, cumulative survival.
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Figure 3. Disease-free survival curve for Rictor. Curve A, lower transcription 
group as determined by moderate prognostic group as defined by NPI serving 
as the dividing line; Curve B, higher transcription group as determined by 
mode rate prognostic group as defined by NPI serving as the dividing line; 
X-axis, follow-up in months; Y-axis, cumulative survival.
Figure 4. Overall survival curve for Rictor. Curve A, lower transcription 
group as determined by moderate prognostic group as defined by NPI serving 
as the dividing line; Curve B, higher transcription group as determined by 
moderate prognostic group as defined by NPI serving as the dividing line; 
X-axis, follow-up in months; Y-axis, cumulative survival.
Table IV. Comparison of Rictor mRNA expression levels in 
subgroups within the cohort.
Patient and tumour
characteristics 95% confidence interval P-value
Tumour grade
 1 vs. 2 -3.1 to 11.5 0.54
 1 vs. 3  0.3 to 46.1 0.01
 2 vs. 3 -0.2 to 4.7 0.039
NPI
 1 vs. 2  0.1 to 8.8 0.03
 1 vs. 3 -0.6 to 9.0 0.16
 2 vs. 3 -2.5 to 1.1 0.73
TNM
 1 vs. 2 -0.7 to 3.7 0.622
 1 vs. 3 -8.5 to 24.2 0.93
 1 vs. 4 -105.9 to 120.4 0.74
 2 vs. 3 -9.0 to 2.1 0.72
 2 vs. 4 -248.9 to 2.6 0.32
 3 vs. 4 -249.4 to 65.1 0.85
Survival
 DF vs. LR -3.3 to 6.4 0.56
 DF vs. DR -98.9 to 13.3 0.68
 DF vs. D -2.0 to 1.8 0.69
Rictor mRNA expression levels (copy number) in a cohort of 150 
breast cancer patients; a comparison between subgroups with different 
tumour grade, Nottingham prognostic index (NPI), TNM stage and 
clinical outcome. DF, disease-free survival; LR, local disease recur-
rence; DR, distant disease recurrence; D, death from breast cancer.
Table V. Comparison of Raptor mRNA expression levels in 
subgroups within the cohort.
Patient and tumour
characteristics 95% confidence interval P-value
Tumour grade
 1 vs. 2 -1,144.2 to 0.0 0.03
 1 vs. 3 -946.7 to 0.0 0.027
 2 vs. 3 -27.8 to 63.0 0.8
NPI
 1 vs. 2 -0.6 to 118.3 0.42
 1 vs. 3 -26.1 to 457.0 0.33
 2 vs. 3 -29.4 to 42.4 0.87
TNM
 1 vs. 2 -225.6 to 1.5 0.46
 1 vs. 3 -0.3 to 1,152.8 0.21
 1 vs. 4  0.0 to 12,201.9 0.034
 2 vs. 3 -0.4 to 4,412.4 0.1076
 2 vs. 4  0.2 to 19,574.1 0.028
 3 vs. 4 -0.01 to 122.43 0.139
Survival
 DF vs. LR -0.0 to 4,873.3 0.1317
 DF vs. DR -1973.0 to 12,654.3 0.5169
 DF vs. D -3.5 to 865.7 0.3875
Raptor mRNA expression levels (copy number) in a cohort of 150 
breast cancer patients; a comparison between subgroups with different 
tumour grade, Nottingham prognostic index (NPI), TNM stage and 
clinical outcome. DF, disease-free survival; LR, local disease recur-
rence; DR, distant disease recurrence; D, death from breast cancer.
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The mTORC1 core protein Raptor mRNA expression was 
higher in the breast cancer specimens, and was found to be 
directly associated with tumour grade (grade 1 vs. 3, P=0.027). 
Paradoxically, it was found to be inversely correlated with 
TNM staging (TNM1 vs. 4, P=0.0343; Table V). Rheb mRNA 
expression was directly associated with tumour grade (grade 1 
vs. 3, P=0.0078; Table VI). The mTORC1 mRNA showed 
a highly significant positive correlation with that of hTERT 
(r=0.585, P<0.00001; Table VII).
Discussion
Rapamycin is macrolide produced by Streptomyces hygro­
scopius. It was initially identified in soil samples taken from 
the Easter Islands, also known as Rapa Nui (9). It was remark-
able for its effect on metabolism and cell growth. During the 
early 1990s, the studies of the effects of rapamycin on yeasts 
led to the discovery of the targets of rapamycin (TOR1 and 2). 
The mammalian targets of rapamycin (mTOR) was described 
shortly thereafter (10).
Initially, it was found that mTOR formed a multi-protein 
complex, later termed mTOR complex 1 (mTORC1). Other 
components of mTORC1 are mammalian lethal with sec-13 
protein 8 (mLST8, also known as GβL), regulatory-associated 
protein of mammalian target of rapamycin (Raptor) (11), DEP 
domain containing mTOR-interacting protein (DEPTOR), 
the Tti1/Tel2 complex, and proline-rich Akt substrate 40 kDa 
(PRAS40) (10). The activity of mTORC1 is inhibited by 
rapamycin and other rapamycin analogues (rapalogues). 
Rapamycin forms a complex with FKBP12, which interacts 
with mTOR subunit of mTORC1 (12).
mTORC1 has been shown to be affected by various stimuli, 
including but not limited to hypoxia, nutritional state, stress, 
growth factors and amino acids. The majority of these stimuli 
are mediated by a number of effectors, such as protein kinase B 
(PKB, also known as Akt), extracellular-signal-regulated 
kinase 1/2 (ERK1/2) and ribosomal S6 kinase (RSK1) (10). 
Typically, these enzymes phosphorylate the tuberous sclerosis 
complex 1 and 2 (TSC1/2, also known as hamartin and tuberin, 
respectively) (13). This inactivates TSC1/2, which when active 
suppresses the activity of Ras homolog enriched in brain 
(Rheb). In such conditions, Rheb activates mTORC1 (14). 
The canonical Wnt pathway interacts with Rheb, as does 
the insulin/PI3K/Akt pathway (15,16). Alternatively, several 
upstream components may interact directly with Rheb. This 
is true with regards to mitogen-activated protein kinase 
(MAPK), which mediates stimuli from p38 (17). PKB/Akt also 
to a certain extent, acts directly upon Rheb. In turn, mTORC1 
regulates lipid metabolism, glycolysis, protein synthesis, cell 
proliferation and autophagy (10,18).
In addition, upstream and downstream components of the 
mTOR pathway have been implicated in carcinogenesis. This 
has marked mTOR as a potential therapeutic target in cancer 
treatment (19). Rapalogues have been clinically proven in the 
treatment of renal cell carcinoma. Their limited side-effect 
profile makes their particularly attractive (4,5). However, rapa-
logues have had limited success as single agents in the case of 
other types of cancers. Considerable efforts have been made 
to identify potential markers of rapamycin sensitivity (7,20).
A less well described complex 2 (mTORC2) was also later 
identified. Similar to mTORC1, it is composed of the mTOR, 
mLST8, DEPTOR and Tti1/Tel2 complex (10). In addition 
it also contains rapamycin-insensitive companion of mTOR 
Table VI. Comparison of Rheb mRNA expression levels in 
subgroups within the cohort.
Patient and tumour
characteristics 95% confidence interval P-value
Tumour grade
 1 vs. 2 -1044.6 to 0.0 0.0127
 1 vs. 3 -0.26 to -0.01 0.0078
 2 vs. 3 0.1 to 12.2 0.1768
Rheb mRNA expression levels (copy number) in a cohort of 150 
breast cancer patients; a comparison between subgroups with different 
tumour grade.
Table VII. Pearson moment-product correlations.
  Rictor Raptor hTERT Rheb
mTOR
 Correlation coefficient 0.221 -0.0249 0.585 -0.0294
 P-value 0.0189 0.812 4.417E-011 0.778
Rictor
 Correlation coefficient  -0.0515 0.181 -0.0639
 P-value  0.620 0.0614 0.538
Raptor
 Correlation coefficient   0.0172 -0.0241
 P-value   0.873 0.828
hTERT
 Correlation coefficient    -0.0482
 P-value    0.654
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(Rictor) (21), mammalian stress-activated map kinase-inter-
acting protein 1 (mSin1), and protein observed with Rictor 1 
and 2 (protor1/2) (3). mTORC2 is not sensitive to rapamycin. 
Our understanding of the role of mTORC2 in the wider 
pathway is still evolving. It has been found to have a role in 
the regulation of cell survival and the cytoskeleton through the 
stimulation of various kinases, including Akt/PKB. Through 
Akt/PKB, it is also thought to inhibit mTORC1 (22).
hTERT is one of the three components of the telomerase 
complex, the others being the RNA template (hTR), and the 
associated protein (TEP-1). This complex repairs the sequences 
on the ends of chromosomes, which are termed telomeres. This 
function prevents cell senescence, and could be related with cell 
immortality (23). Increased hTERT activity has been implicated 
in various neoplastic diseases, including breast carcinoma (24). 
In endometrial carcinoma, rapamycin has been demonstrated 
to reduce hTERT mRNA expression (25). On the other hand, 
in hepatocellular carcinoma, rapamycin has been found to 
exert a post-transcriptional inhibitory effect on hTERT activity. 
However, no effect was found on hTERT mRNA expression (26). 
Evidence for a regulatory role for mTOR on telomerase activity 
has been found in the case of adult T cell leukaemia (27). hTERT 
activity has been suggested as a surrogate for rapamycin anti-
neoplastic activity in endometrial carcinoma (25). Our finding of 
a highly significant positive correlation between mTORC1 and 
hTERT lends further support to the hypothesis that mTORC1 is 
an important regulator of hTERT and telomerase.
Our study shows significant correlations between the 
expression of mTORC1 and parameters of advanced disease 
in mammary carcinogenesis, including tumour grade and NPI 
and an inverse relationship to overall survival. This reiterates 
the potential for a therapeutic role for mTORC1 inhibitors in 
human breast cancer. The correlation of mTORC1 expression 
with ductal carcinoma suggests that such therapeutic agents 
may be more effective in treating patients with invasive ductal 
carcinoma. Our findings also suggest that mTORC1 may exert 
its carcinogenic effect through the upregulation of hTERT.
Whilst Raptor's association with worsening tumour grade 
is consistent with its role in mTORC1, its paradoxical relation-
ship with TNM stage would require further study along with 
other components of mTORC1.
This is the first study to show an inverse relationship 
between the Rictor subunit of mTORC2, NPI and tumour 
grade, as well as demonstrate a significant direct correlation 
of Rictor expression with disease-free and overall survival. 
This is suggestive of a more extensive countervailing role of 
mTORC2 versus mTORC1 than previously postulated.
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